VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC

Anne Covey, MD
Published: Thursday, Mar 31, 2016



Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

For patients with limited disease (small HCC), the guidelines now include ablation as a potentially curative option. Prior to this change, surgery and transplant were the only curative therapies, Covey says.

The locoregional therapy panel has also expanded to include patients with minimal extrahepatic disease who are candidates for arterially directed therapies. Finally, Covey says, select patients who have tumor in the portal vein—this used to be considered a contraindication—can now receive locoregional therapy.

Covey says there needs to be work done to include imaging follow-up for locoregional therapy in NCCN guidelines. There are several techniques to evaluate response, she says, but the information should be included in guidelines.

<<< View more from the 2016 NCCN Annual Conference



Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

For patients with limited disease (small HCC), the guidelines now include ablation as a potentially curative option. Prior to this change, surgery and transplant were the only curative therapies, Covey says.

The locoregional therapy panel has also expanded to include patients with minimal extrahepatic disease who are candidates for arterially directed therapies. Finally, Covey says, select patients who have tumor in the portal vein—this used to be considered a contraindication—can now receive locoregional therapy.

Covey says there needs to be work done to include imaging follow-up for locoregional therapy in NCCN guidelines. There are several techniques to evaluate response, she says, but the information should be included in guidelines.

<<< View more from the 2016 NCCN Annual Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x